Real-world evidence on all-oral, interferon-free regimens with Ombitasvir/Paritaprevir/r and Dasabuvir for treatment of chronic HCV patients with renal insufficiency in the German Hepatitis C-Registry

2016 ◽  
Vol 54 (12) ◽  
pp. 1343-1404
Author(s):  
H Hinrichsen ◽  
J Wiegand ◽  
E Schott ◽  
P Buggisch ◽  
G Gerken ◽  
...  
2019 ◽  
Vol 70 (1) ◽  
pp. e329 ◽  
Author(s):  
Joseph Doyle ◽  
Daniela van Santen ◽  
David lser ◽  
Joe Sasadeusz ◽  
Mark O’reilly ◽  
...  

2021 ◽  
Author(s):  
Brian Conway ◽  
Sergio Rodriguez-Tajes ◽  
Montserrat Garcia-Retortillo ◽  
Paco Pérez-Hernandez ◽  
Elisabetta Teti ◽  
...  

Background: People experiencing homelessness are disproportionately affected by hepatitis C virus (HCV) and can face specific barriers to care. Simple treatment algorithms could increase linkage to care in this population. Methods: This retrospective real-world analysis pooling data from 15 clinical cohorts evaluated effectiveness of a once-daily sofosbuvir/velpatasvir (SOF/VEL) regimen in HCV-infected people experiencing homelessness. The primary outcome was sustained virological response (SVR) in the effectiveness population (patients with confirmed SVR status). Secondary outcomes included reasons for not achieving SVR, adherence and time between diagnosis and SOF/VEL treatment start. Results: Of 153 patients treated with SOF/VEL for 12 weeks without ribavirin, SVR was 100% in the effectiveness population (n = 122), irrespective of various baseline factors including active injecting drug use and presence of mental health disorders. Conclusion: HCV-infected people experiencing homelessness can successfully be treated with SOF/VEL. SOF/VEL enables implementation of simple treatment algorithms and can support test-and-treat strategies through rapid treatment starts and minimal monitoring.


2017 ◽  
Vol 20 (9) ◽  
pp. A791 ◽  
Author(s):  
I Gomes ◽  
A Figueira ◽  
C Sequeira ◽  
S Silva ◽  
F Machado ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document